A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

NCT05972044 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

516

Enrollment

INDUSTRY

Sponsor class

Conditions

ADHD

Interventions

DRUG: Solriamfetol 150 mg
DRUG: Solriamfetol 300 mg
DRUG: Placebo

Sponsor

Axsome Therapeutics, Inc.